RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter and Six Months ended September 30, 2010
Currency: Indian Rupees (Rs.) with U.S. Dollar (U.S.$) convenience translation (Rate: Rs. 44.56 = U.S.$1.00)
Business Overview: DRL is a leading India-based pharmaceutical company operating in three segments: Pharmaceutical Services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Principal operations include manufacturing in India and Mexico, with marketing in India, Russia, the U.S., Europe, and other regions.

Key Financial Metrics

Figures in millions unless otherwise noted.

Debt Breakdown (as of Sep 30, 2010):
- Short-term borrowings: Rs. 7,177 million
- Long-term borrowings (current portion): Rs. 4,945 million
- Long-term borrowings (non-current): Rs. 2,372 million

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 2% quarter-over-quarter (QoQ) and decreased 3% year-over-year (YoY) for the six-month period. The QoQ increase was driven by the Global Generics segment (+8%), while PSAI revenues declined 14% due to price erosion and lower customer inventories.
• Profitability: Net profit increased 32% QoQ to Rs. 2,868 million. Gross margins improved to 53% (from 47% prior year) due to higher sales of high-margin products and new launches, partially offset by foreign exchange headwinds.
• Geographic Performance:
  • India: Global Generics revenue grew 25% QoQ, driven by volume growth and new product launches (including biosimilars).
  • North America: Revenue grew 3% QoQ (7% excluding currency), driven by new launches, though fexofenadine sales were lower.
  • Germany: Revenue declined 26% QoQ due to price erosion from competitive bidding tenders and lower vaccine sales.
  • Russia: Revenue grew 23% QoQ, with prescription secondary sales growing 34%.
• Expenses: R&D expenses increased 32% QoQ to Rs. 1,270 million. SG&A expenses increased 7% QoQ, largely due to expanded sales forces in India and Russia.
• Foreign Exchange: The appreciation of the Indian Rupee against the U.S. Dollar and Euro resulted in a net foreign exchange loss of Rs. 49 million for the quarter, compared to a gain of Rs. 245 million in the prior year.

Guidance, Outlook, Risks, and Unusual Items

• Tax Outlook: Management expects the effective tax rate for the fiscal year ending March 31, 2011, to be approximately 12%, down from 22.25% in the prior year, due to enhanced weighted deductions on R&D expenses under the Indian Union Budget.
• Recent Developments:
  • GSK Acquisition: On November 22, 2010, DRL agreed to acquire GSK's oral penicillin facility in the U.S. and certain product portfolios. Closing is expected before June 30, 2011.
  • Brazil Sale: Sold marketing authorizations and dossiers for a product portfolio in Brazil to GSK Brazil for a total consideration of U.S.$13 million (Rs. 604 million), including an upfront payment of U.S.$4 million.
  • German Tenders: Germany's largest health insurance fund (AOK) announced a new tender for 87 off-patent drugs, creating continued pricing pressure in the German market.
• Legal and Regulatory Risks:
  • Patent Litigation: Ongoing U.S. litigation regarding Fexofenadine (Allegra) with a preliminary injunction granted against DRL's launch of a higher-strength combination product; trial scheduled for January 2011. Litigation continues in Germany regarding Alendronate Sodium and Oxycodon.
  • Regulatory Investigations: Subpoenas and Civil Investigative Demands from U.S. Attorneys General (Florida, Virginia, Michigan) regarding marketing practices of certain products (ranitidine, fluoxetine, buspirone) sold by a subsidiary.
  • Ceragenix Bankruptcy: DRL is objecting to the sale of assets by Ceragenix (bankrupt partner) which could impact the carrying value of intangible assets related to the EpiCeram product.
• Unusual Items:
  • Severance Payments: Continued recognition of severance costs related to restructuring of German subsidiaries (betapharm).
  • Inventory Write-downs: Rs. 586 million recorded for the six months ended Sep 30, 2010.

Investor Verification Checklist

• German Market Exposure: Verify the impact of competitive bidding tenders and price erosion on the German subsidiary (betapharm) and the sustainability of the "high volume, low margin" business model.
• U.S. Patent Litigation: Monitor the outcome of the Fexofenadine litigation (trial Jan 2011) and potential damages or sales restrictions.
• Currency Sensitivity: Assess the impact of Indian Rupee appreciation on future revenue recognition, given significant U.S. Dollar and Euro exposure.
• Regulatory Investigations: Track the status of U.S. state Attorney General investigations regarding marketing practices.
• GSK Transaction: Confirm the closing of the U.S. manufacturing facility acquisition and integration plans.
• Debt Structure: Review the mix of short-term vs. long-term borrowings and interest rate exposure (LIBOR/EURIBOR linked).